NEW YORK (GenomeWeb News) – Ontario’s Queen’s University is using a gene expression analysis system from Xceed Molecular in its efforts to develop technology that will help predict clinical outcomes for follicular lymphoma patients, the company said yesterday.
Queen’s College researcher Harriet Feilotter will lead studies using Xceed’s Ziplex System to validate a gene expression signature linked to a type of this form of non-Hodgkin lymphoma. This cancer grows slowly, and it mainly affects older adults, both men and women in equal numbers.
“Currently there are no molecular diagnostic tools on the market that can predict which primary tumors will be aggressive,” Feilotter said in a statement, but having an easy way to gauge individual risk will help doctors develop beneficial treatment plans.
Xceed President and CEO David Deems said in a statement that Feilotter’s follicular lymphoma studies, which use both archival and fresh frozen tissues as source samples, show "great promise,” and have "implications far beyond this particular research study.”
Financial terms of the agreement were not released.